JP2025500321A5 - - Google Patents

Info

Publication number
JP2025500321A5
JP2025500321A5 JP2024537118A JP2024537118A JP2025500321A5 JP 2025500321 A5 JP2025500321 A5 JP 2025500321A5 JP 2024537118 A JP2024537118 A JP 2024537118A JP 2024537118 A JP2024537118 A JP 2024537118A JP 2025500321 A5 JP2025500321 A5 JP 2025500321A5
Authority
JP
Japan
Prior art keywords
independently selected
optionally substituted
compound according
occurrence
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/053910 external-priority patent/WO2023122320A1/en
Publication of JP2025500321A publication Critical patent/JP2025500321A/ja
Publication of JP2025500321A5 publication Critical patent/JP2025500321A5/ja
Pending legal-status Critical Current

Links

JP2024537118A 2021-12-24 2022-12-23 多脚型セロトニン作動性化合物ならびにセロトニン受容体アゴニスト及びアンタゴニストのプロドラッグ Pending JP2025500321A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163293730P 2021-12-24 2021-12-24
US63/293,730 2021-12-24
US202263299817P 2022-01-14 2022-01-14
US63/299,817 2022-01-14
US202263338994P 2022-05-06 2022-05-06
US63/338,994 2022-05-06
PCT/US2022/053910 WO2023122320A1 (en) 2021-12-24 2022-12-23 Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists

Publications (2)

Publication Number Publication Date
JP2025500321A JP2025500321A (ja) 2025-01-09
JP2025500321A5 true JP2025500321A5 (https=) 2026-01-06

Family

ID=86903690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537118A Pending JP2025500321A (ja) 2021-12-24 2022-12-23 多脚型セロトニン作動性化合物ならびにセロトニン受容体アゴニスト及びアンタゴニストのプロドラッグ

Country Status (3)

Country Link
EP (1) EP4452939A4 (https=)
JP (1) JP2025500321A (https=)
WO (1) WO2023122320A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
AU2023319280A1 (en) * 2022-08-05 2025-03-20 Mindset Pharma Inc. 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
WO2024081961A2 (en) * 2022-10-14 2024-04-18 Invyxis, Inc. Ester analogs of psilocin, processes for the preparation thereof, and methods of use
WO2025045773A1 (en) * 2023-08-25 2025-03-06 Compass Pathfinder Limited 3-(2-(dimethylamino)ethyl)-1h-indol-4-yl oligomeric derivatives
WO2025122513A1 (en) * 2023-12-04 2025-06-12 Delix Therapeutics, Inc. Methods of treating neuropsychiatric disorders with non-hallucinogenic tryptamines
US20260021070A1 (en) * 2024-07-19 2026-01-22 Compass Pathfinder Limited Subcutaneous formulations comprising psilocybin derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2731223A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives bi-tryptaminiques, leur procede de preparation et leur utilisation a titre de medicaments
EP2771341A4 (en) * 2011-10-28 2015-09-23 Univ Texas NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
JP2016521683A (ja) * 2013-05-24 2016-07-25 ネステク ソシエテ アノニム 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
BR112022015379A2 (pt) * 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
CA3188636A1 (en) * 2020-08-21 2022-02-24 Matthias GRILL Novel psilocin derivatives having prodrug properties
AU2023234202A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
AU2023319280A1 (en) * 2022-08-05 2025-03-20 Mindset Pharma Inc. 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
CN120091999A (zh) * 2022-08-05 2025-06-03 思维模式制药公司 作为血清素能剂用于治疗相关病症的3-吡咯烷-吲哚二聚体
WO2024081961A2 (en) * 2022-10-14 2024-04-18 Invyxis, Inc. Ester analogs of psilocin, processes for the preparation thereof, and methods of use

Similar Documents

Publication Publication Date Title
JP2025500321A5 (https=)
JP2024531229A5 (https=)
DK153940C (da) Analogifremgangsmaade til fremstilling af 1-aryloxy-3-alkylamino-2-propanol-derivater eller farmaceutisk anvendelige, ugiftige syreadditionssalte deraf
Lu et al. Transition metal-free direct trifluoromethylthiolation of indoles using trifluoromethanesulfonyl chloride in the presence of triphenylphosphine
JP2022545633A5 (https=)
JP2010528089A5 (https=)
JP2011016800A5 (https=)
IN2014CN00532A (https=)
JP2015532275A5 (https=)
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
RU2009133453A (ru) Фторсодержащее пиразолкарбонитрильное производное и способ его получения и фторсодержащее производное пиразолкарбоновой кислоты, полученное с применением фторсодержащего пиразолкарбонитрильного производного и способ его получения
JPWO2022138968A5 (https=)
JP2023518776A5 (https=)
JP2025507292A5 (https=)
Feraldi‐Xypolia et al. Synthesis of Functionalized 4‐Fluoropyridazines
IL318795A (en) 3-Ethylaminoindole dimers as serotonergic agents useful for the treatment of related disorders
KR900006307A (ko) 단백질 키나아제 c억제제로서 유용한 신규 퀴놀릴옥사졸-2-온
KR920009802A (ko) 치환된 아졸, 이의 제조방법, 이를 함유하는 제제 및 이의 용도
JP2010235601A5 (https=)
Ryabov et al. Structural and mechanistic look at the orthoplatination of aryl oximes by dichlorobis (sulfoxide or sulfide) platinum (II) complexes
Li et al. Transition-metal-free amination phosphoryl azide for the synthesis of phosphoramidates
JP2018090537A5 (https=)
Erb et al. Synthesis of Ferrocenesulfonyl Chloride: Key Intermediate toward Ferrocenesulfonamides
IL318794A (en) 3-Pyrrolidine Indole Dimers as Serotonergic Agents Useful for the Treatment of Related Disorders
Zaguzin et al. Strong halogen bonds with guest molecules in a Co (ii) 2, 5-diiodoterephthalate metal–organic framework